Bellevue Life Sciences Acquisition Past Earnings Performance
Past criteria checks 0/6
Bellevue Life Sciences Acquisition has been growing earnings at an average annual rate of 3.4%, while the Capital Markets industry saw earnings growing at 7.9% annually.
Key information
3.4%
Earnings growth rate
7.3%
EPS growth rate
| Capital Markets Industry Growth | 10.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Bellevue Life Sciences Acquisition makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | 0 | 2 | 0 |
| 30 Jun 24 | 0 | 0 | 2 | 0 |
| 31 Mar 24 | 0 | 0 | 2 | 0 |
| 31 Dec 23 | 0 | 0 | 2 | 0 |
| 30 Sep 23 | 0 | 0 | 1 | 0 |
| 30 Jun 23 | 0 | 0 | 1 | 0 |
| 31 Mar 23 | 0 | 0 | 0 | 0 |
| 31 Dec 22 | 0 | 0 | 0 | 0 |
| 30 Sep 22 | 0 | 0 | 0 | 0 |
| 30 Jun 22 | 0 | 0 | 0 | 0 |
| 31 Mar 22 | 0 | 0 | 0 | 0 |
| 31 Dec 21 | 0 | 0 | 0 | 0 |
Quality Earnings: BLAC is currently unprofitable.
Growing Profit Margin: BLAC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BLAC is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare BLAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLAC is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (13.2%).
Return on Equity
High ROE: BLAC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.